About this trial
Ofloxacin is a gold standard antibiotic for the treatment of bone and joint infections due to sensible staphylococcus strains. However, in the elderly, inter-individual variability of the pharmacokinetics may reduce the efficacy or increase toxicity. The occurrence of ofloxacin side effects is likely to be increased in case of higher exposition. However, the serum concentration-toxicity relationship has not yet been determined. The purpose of this project is to assess the association between the residual serum concentration of ofloxacin at day 3 and the occurrence of at least one adverse effect attributable to ofloxacin, and determine a threshold toxicity concentration if this association exists.
Eligibility criteria
Qualifiers
Patients aged over 65 years hospitalized at the University Hospital of Amiens for an uncomplicated bone and joint infections
Indication for oral switch to ofloxacin
Disqualifiers
Patient refusing to participate in the study
Patient under guardianship or curators or deprived of public rights
Any liver or biliary injury
Any contraindications to ofloxacin
Trial design
Treatments tested in this trial
- ofloxacin
- questionnaire
- Ofloxacin Serum concentration
Treatment groups
Locations
1Sponsors and collaborators
Centre Hospitalier Universitaire, Amiens
Lead sponsor